BridgeBio Pharma (BBIO) Long-Term Investments (2018 - 2026)

BridgeBio Pharma has disclosed Long-Term Investments across 7 years of filings, most recently posting $61.5 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $61.5 million, down 52.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.5 million (down 52.0% YoY), and the FY2025 annual result was $80.0 million, down 44.37% from the prior year.
• Long-Term Investments came in at $61.5 million for Q1 2026 at BridgeBio Pharma, down from $80.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $160.4 million in Q3 2024 to a low of $61.5 million in Q1 2026.
• The 3-year median for Long-Term Investments is $112.5 million (2024), against an average of $111.4 million.
• Across the five-year window, Long-Term Investments decreased 7.7% in 2025 and plunged 52.0% in 2026, its largest moves.
• BridgeBio Pharma's Long-Term Investments stood at $143.7 million in 2024, then plunged by 44.37% to $80.0 million in 2025, then slipped by 23.06% to $61.5 million in 2026.
• The last three Long-Term Investments figures came in at $61.5 million (Q1 2026), $80.0 million (Q4 2025), and $92.2 million (Q3 2025), per Business Quant data.